Skip to main content

Janus Henderson Investors — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

227
Companies
$31.3B
Total invested
$160.4M
Avg. check
21
Industries
Biotechnology 20Health Care 19Medical 8Therapeutics 7Pharmaceutical 6Biopharma 5+15 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 227
Ocugen
May 2026

Ocugen is a biotechnology company that develops novel gene and cell therapies to improve health and patient outcomes.

Biopharma · Malvern$115.0M Post-IPO Debt
Windward Bio
May 2026

Windward Bio develops monoclonal antibodies for advanced immunological diseases.

Biotechnology · Basel$165.0M Series B
CARGO Therapeutics
May 2024

CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.

Biotechnology · San Mateo$110.0M Post-IPO Equity
Chinook Therapeutics
May 2022

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science.

Biotechnology · Vancouver$105.0M Post-IPO Equity
P3 Health Partners
May 2024

P3 Health Partners is a patient-centered, physician-led and population health-focused healthcare company.

Finance · Henderson$42.2M Post-IPO Equity
Starlab Space
May 2026

Developing the next-generation, AI-enabled commercial space station

Aerospace · WebsterVenture - Series Unknown
Everest Medicines
May 2026

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients.

Biotechnology · New York$6.8M Post-IPO Secondary
ITeos Therapeutics
May 2024

ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.

Biotechnology · Cambridge$120.0M Post-IPO Equity
Forte Biosciences
April 2026

Forte Biosciences is a biotechnology company that focuses on dermatology.

Biotechnology · Sherman Oaks$150.0M Post-IPO Equity
IntelyCare
April 2022

IntelyCare is revolutionizing healthcare staffing, scheduling, and training by offering an enterprise workforce management platform.

Health Care · Quincy$115.0M Series C
Obsidian Therapeutics
April 2024

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

Biotechnology · Cambridge$160.5M Series C
Climb Bio
April 2026

Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.

Biotechnology · Redmond$110.0M Post-IPO Equity
Edgewise Therapeutics
April 2025

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Biopharma · Boulder$200.0M Post-IPO Equity
Maze Therapeutics
April 2026

Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.

Biopharma · South San Francisco$150.0M Post-IPO Equity
Ray Therapeutics
April 2026

Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.

Biotechnology · San Diego$125.0M Series B
Calyxo
April 2026

Calyxo is a medical device company that improves kidney stone treatment through specialized urology technologies.

Health Care · Pleasanton$40.0M Series F
AN2 Therapeutics
March 2026

AN2 Therapeutics focuses on modern biomedical and drug development expertise to provide transformational medicines.

Biotechnology · Menlo Park$40.0M Post-IPO Equity
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post-IPO Equity
Akero Therapeutics
March 2024

Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

Biotechnology · Cambridge$366.9M Post-IPO Equity
Ambrosia Biosciences
March 2026

Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.

Biopharma · Boulder$100.0M Series B
Palisade Bio
March 2026

Palisade Bio is a clinical-stage biopharmaceutical company that develops therapies for acute and chronic gastrointestinal complications.

Biopharma · Carlsbad$3.0M Post-IPO Equity
Stoke Therapeutics
March 2024

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.

Biotechnology · Bedford$125.0M Post-IPO Equity
Heartflow
March 2025

Heartflow is a medical technology company that provides various methods of diagnosis and treatment of cardiovascular disease.

Artificial Intelligence (AI) · Mountain View$98.0M Convertible Note
Nkarta Therapeutics
March 2024

Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies.

Biotechnology · South San Francisco$240.0M Post-IPO Equity

Where Janus Henderson Investors invests

Biotechnology20
Health Care19
Medical8
Therapeutics7
Pharmaceutical6
Biopharma5

About Janus Henderson Investors's portfolio

How many companies has Janus Henderson Investors invested in?

Janus Henderson Investors has invested in 227 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Janus Henderson Investors invest in?

Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 21 different industry categories.

What is Janus Henderson Investors's largest investment?

Among tracked funding rounds, Akero Therapeutics received $366.9M in a Post-IPO Equity round. Janus Henderson Investors's total known invested capital is $31.3B.

What is the average investment size for Janus Henderson Investors?

Janus Henderson Investors's average investment size is $160.4M across its portfolio of 227 companies.

What are Janus Henderson Investors's most recent investments?

Recent Janus Henderson Investors portfolio additions include Ocugen, Windward Bio, CARGO Therapeutics, Chinook Therapeutics, P3 Health Partners. These companies were founded in 2020 or later.

Reach the founders behind these 227 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →